CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Allergan plc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Allergan plc
Clonshaugh Business And Technology Park
Phone: +353 2165235000p:+353 2165235000 DUBLIN, D17 E400  Ireland Ticker: AGNAGN

Business Summary
Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US General Medicine and International. The US Specialized Therapeutics segment includes sales relating to branded products within the United States, including Medical Aesthetics, Medical Dermatology, Eye Care, Neurosciences and Urology therapeutic products. The US General Medicine segment includes sales relating to branded products within the United States that do not fall into the US Specialized Therapeutics business units, including Central Nervous System, Gastrointestinal, Women's Health, Anti-Infectives and Diversified Brands. The International segment includes sales relating to products sold outside the United States.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-Yes--Yes--

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201912/31/2018YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, President, Chief Executive Officer Brenton L.Saunders 49 10/26/2016 7/1/2014
Chief Financial Officer, Executive Vice President Matthew M.Walsh 52 2/20/2018 2/20/2018
Chief Human Resource Officer, Executive Vice President Karen L.Ling 55 7/1/2014 7/1/2014
10 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Actavis Capital S.a.r.l. Luxembourg
Warner Chilcott Finance LLC UNITED STATES
Eurand N.V. Olympic Plaza Amsterdam Netherlands
56 additional Subsidiary records available in full report.

Business Names
Business Name
0Y7T
Actavis Acquisition 1 S.a.r.l.
Actavis Acquisition 2 S.a.r.l.
241 additional Business Names available in full report.

General Information
Number of Employees: 16,900 (As of 12/31/2018)
Outstanding Shares: 328,277,336 (As of 11/1/2019)
Shareholders: 3,176
Stock Exchange: NYSE
Federal Tax Id: 953872914


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, December 06, 2019